alexa Effect of smokeless tobacco (snus) on smoking and public health in Sweden.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Foulds J, Ramstrom L, Burke M, Fagerstrm K

Abstract Share this page

Abstract OBJECTIVE: To review the evidence on the effects of moist smokeless tobacco (snus) on smoking and ill health in Sweden. METHOD: Narrative review of published papers and other data sources (for example, conference abstracts and internet based information) on snus use, use of other tobacco products, and changes in health status in Sweden. RESULTS: Snus is manufactured and stored in a manner that causes it to deliver lower concentrations of some harmful chemicals than other tobacco products, although it can deliver high doses of nicotine. It is dependence forming, but does not appear to cause cancer or respiratory diseases. It may cause a slight increase in cardiovascular risks and is likely to be harmful to the unborn fetus, although these risks are lower than those caused by smoking. There has been a larger drop in male daily smoking (from 40\% in 1976 to 15\% in 2002) than female daily smoking (34\% in 1976 to 20\% in 2002) in Sweden, with a substantial proportion (around 30\%) of male ex-smokers using snus when quitting smoking. Over the same time period, rates of lung cancer and myocardial infarction have dropped significantly faster among Swedish men than women and remain at low levels as compared with other developed countries with a long history of tobacco use. CONCLUSIONS: Snus availability in Sweden appears to have contributed to the unusually low rates of smoking among Swedish men by helping them transfer to a notably less harmful form of nicotine dependence.
This article was published in Tob Control and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

  • Limin Chen
    An 18- Gene Signature Predicting Treatment Response to Interferon in Patients Chronically Infected with Hepatitis C Virus
    PPT Version | PDF Version
  • Sudha Srivastava
    Novel Inhibitor by Modifying Oseltamivir Based on Neuraminidase Structure for Treating Drug-Resistant H5N1 Virus Using Molecular Docking NMR and DSC Methods
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords